摘要:
The compositions and compounds of formula I, formula II, formula III which includes a molecular conjugate with ornithine or its polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection administration. Such compositions may be used to the treatment of urea cycle disorders and hepatic diseases or its associated complications.
摘要:
The compositions and compounds of formula I, formula II, formula III and formula IV which includes a salt of valproic acid or its polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III and formula IV and methods for treating or preventing neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of epilepsy, bipolar disorder, migraine, schizophrenia, depression, Alzheimer's disease, cancer, HIV and familial adenomatous polyposis.
摘要:
The present invention describes a synergistic composition comprising of one or more statins, or one or more dipeptidyl peptidase IV (DPP IV) inhibitor or one or more biguanide antihyperglycaemic agent and a PPAR agonist of formula (la) for the treatment of diabetes, especially non-insulin dependent diabetes (NIDDM) or Type 2 diabetes and conditions associated with diabetes mellitus and to compositions suitable for use in such method. The invention also describes the preparation of such compositions. The present invention also relates to certain novel salts of the PPAR agonist of formula (I), processes for the preparation of : these novel salts and use thereof.
摘要:
Novel synthesized amino acids of glutamine and lysine that are directly PEGylated with small, monodisperse PEGs, and a novel process for creating novel amino acid monomers using PEGylation. These amino acids are readily incorporated into peptides for a range of different applications.
摘要:
Die Erfindung betrifft neue Salze von 1-(3-Methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1R)- 4-(trifluormethyl)-2,3-dihydro-1H-inden-1-yl]-1,2,3,4-tetrahydropyrimidin-5-carbonsäure der Formel (I),insbe- sondere Aminosäuresalze wie das Lysinsalz und Alkalimetallsalze wie das Natriumsalz und das Kaliumsalz, Verfahren zu deren Herstellung, diese enthaltende Arzneimittel sowie deren Verwendung bei der Bekämpfung von Krankheiten.
摘要:
L'invention concerne un procédé de racémisation de la L-lysine permettant d'obtenir en continu une solution aqueuse à 30-35% en poids de D, L-lysine. On mélange une poudre de L-lysine dans de l'acide acétique glacial et on chauffe à 100°C en présence d'une quantité catalytique d'acétyl-salicylaldéhyde; on évapore l'acide acétique jusqu'à obtention d'un résidu huileux, que l'on dilue à l'eau et que l'on soumet à une extraction liquide/liquide au moyen d'un solvant, on sélectionne la phase aqueuse obtenue et on la fait passer sur une résine échangeuse d'ions. L'invention concerne aussi une utilisation de la solution de D, L-lysine obtenue comme matière première d'un procédé de préparation en continu d'un sel d'acide O-acétylsalicylique de D, L-lysine. L'invention concerne enfin une installation pour la mise en œuvre en continu du procédé selon l'invention.
摘要:
Provided herein are lipidoids that may be prepared from the conjugate addition of alkylamines to acrylates. In some embodiments, provided lipidoids are biodegradable and may be used in a variety of drug delivery systems. Given the amino moiety of the lipidoids, they are well-suited for the delivery of polynucleotides, in addition to other agents. Nanoparticles containing the inventive lipidoids and polynucleotides have been prepared and have been shown to be effective in delivering siRNA.
摘要:
Described herein are compounds and compositions that are characterized by the Markush formulae (I), (II), (III), (IV), (V), and (VI) underneath, where at least one terminal amino group is further functionalized by bearing a group of type (i), (ii) or (iii). Such compounds are obtained by reacting the terminal amino group with epoxides or acrylates bearing long chain hydrocarbon groups. The resulting amphiphilic molecules (named "APPLs" in the application) are deemed useful as drug delivery system including nucleotide delivery to cells. Formulae (i), (ii), and (iii) are:
摘要:
The present invention provides forms of curcumin and the pharmaceutical compositions thereof. The forms of curcumin disclosed herein are curcumin polymorph Form III, curcumin-2-aminobenzimidazole co-crystal, and curcumin-L-lysine co-crystal. Further, the invention provides methods inhibiting cancer cells and HSV-1 using these curcumin novel solid forms.